Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 1997

View Archived Issues

Hyalgan introduced in U.S. for osteoarthritis of the knee

First approval for irbesartan

Shire acquires Richwood

North American clinical trials with LiquiVent to be reinitiated

ArQule and GenQuest cancer collaboration

NDA for Colazide accepted for review by FDA

FDA clears new formulation of Imitrex

FDA requests additional manufacturing data before approval of Rituxan

Small peptides developed at Prolifix induce apoptosis in cancer cells

LU-51198 prevents complement-mediated myocardial injury

What's new in Cardiology? Highlights from the 19th Congress of the European Society of Cardiology

Famotidine for schizophrenia

Migraine prophylaxis with bisoprolol

Soluble TNF receptor may benefit patients with coronary artery disease

Cardiovascular benefits of the Mediterranean diet

Past, present and future of arrhythmia therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.